Acad Pediatr by Cullen, Karen A. et al.
Uptake of Human Papillomavirus Vaccine Among Adolescent 
Males and Females: Immunization Information System Sentinel 
Sites, 2009–2012
Karen A. Cullen, PhD, MPH, Shannon Stokley, MPH, and Lauri E. Markowitz, MD
Immunization Services Division, National Center for Immunization and Respiratory Diseases, 
Centers for Disease Control and Prevention, Atlanta, Ga (Dr Cullen and Ms Stokley); and Division 
of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 
Centers for Disease Control and Prevention, Atlanta, Ga (Dr Markowitz)
Abstract
Objective—The Advisory Committee on Immunization Practices (ACIP) has recommended 
routine human papillomavirus (HPV) vaccination at age 11 or 12 years for girls since 2006 and for 
boys since 2011. We sought to describe adolescent HPV vaccination coverage, doses administered 
from 2009 to 2012, and age at first vaccination by sex.
Methods—Aggregate data were analyzed from 8 Immunization Information System sentinel 
sites on HPV vaccinations in children and adolescents aged 11 to 12 years, 13 to 15 years, and 16 
to 18 years. Vaccination coverage by age group was reported for 2009 to 2012, and weekly doses 
administered were determined. Age at first HPV vaccination was calculated for girls in 2007 and 
2011 and for boys in 2011.
Results—This analysis included data on 2.9 million adolescents aged 11 to 18 years. There were 
small increases in coverage for girls, with receipt of ≥1 dose of HPV vaccine reaching 27.1% of 
ages 11 to 12, 47.9% of ages 13 to 15, and 57.1% of ages 16 to 18 by December 31, 2012. Uptake 
of ≥1 dose in boys reached ~18% for all age groups. Doses administered showed seasonal 
variation, with highest uptake before back to school among girls and steady increases in boys after 
the 2009 ACIP recommendation for permissive use. Doses administered to boys surpassed those 
administered to girls by September 2012. Among vaccinated girls, more received vaccine at the 
recommended age of 11 to 12 years in 2011 (74.2%) compared to 2007 (9.9%). In 2011, 27.3% of 
vaccinated boys received their first dose at age 11 to 12 years.
Conclusions—HPV vaccination coverage increased among adolescents between 2009 and 
2012. However, increases among girls were small, and coverage for boys and girls remained 
below target levels.
Address correspondence to Karen A. Cullen, PhD, MPH, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Mailstop 
A-06, Atlanta, GA 30333 (kcullen@cdc.gov).. 
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers 
for Disease Control and Prevention.
The authors declare that they have no conflict of interest.
HHS Public Access
Author manuscript
Acad Pediatr. Author manuscript; available in PMC 2015 October 05.
Published in final edited form as:














adolescent; human papillomavirus vaccine; immunization
QUADRIVALENT AND BIVALENT human papillomavirus (HPV) vaccines were licensed for use in girls in 
2006 and 2009, respectively.1 In 2009, the quadrivalent HPV vaccine was licensed for use in 
boys.2 The Advisory Committee on Immunization Practices (ACIP) recommended routine 
vaccination, involving a series of 3 doses, for 11- or 12-year-old girls in 20063 and for 11- or 
12-year-old boys in 2011.2 For male subjects, the recommendation for routine use followed 
guidance by ACIP stating that quadrivalent HPV vaccine may be provided to male subjects 
aged 9 to 26 years since October 2009.2 In 2012, data from the National Immunization 
Survey–Teen (NIS-Teen) showed that 53.8% of female adolescents 13 to 17 years of age in 
the United States had received ≥1 HPV vaccine dose, and 33.4% had received 3 doses.4 
Data from 2012 NIS-Teen also indicated that 20.8% of male adolescents 13 to 17 years of 
age had received ≥1 HPV vaccine dose, and 8.3% had received 3 doses.4
The NIS is the main source of vaccine coverage data for children and adolescents in the 
United States and is used to monitor progress toward the Healthy People 2020 targets for 
vaccination coverage. The target is 80% 3-dose coverage among adolescent girls by the age 
of 13 to 15 years. In addition to the NIS, data from Immunization Information System (IIS) 
can be used to obtain coverage data. The NIS-Teen collects vaccination information for 
adolescents aged 13 to 17 years in the United States using a random-digit-dialed sample of 
landline and, starting in 2011, cellular telephone numbers. Parents/guardians provide 
vaccination and sociodemographic information on the adolescent and are asked for 
permission to contact their child’s vaccination provider. The provider is mailed a 
questionnaire to obtain a vaccination history from the medical record.5,6 Data from IIS can 
serve as useful complements to NIS-Teen because IIS typically covers wider age ranges and 
may be able to provide local estimates; in addition, IIS data have been used to provide more 
timely information regarding vaccine use.7–9
The objectives of this study were to use IIS to examine vaccination coverage and doses 
administered in male and female adolescents from October 2009 through December 2012 to 




An IIS is a confidential, computerized, population-based information system that collects 
and consolidates vaccination data from vaccination providers. It also provides important 
tools for designing and sustaining effective immunization strategies at the provider and 
immunization program levels. These tools include clinical decision support, vaccination 
coverage reports, interoperability with electronic health record systems, and vaccine 
inventory management, as well as the ability to generate reminder and recall messages.10 
The IIS Sentinel Site Project is a collaborative project between the US Centers for Disease 
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Control and Prevention (CDC) and selected state/city-based IIS to implement procedures to 
increase data completeness, timeliness, and accuracy. Data are also used for immunization 
program evaluation and vaccination coverage estimates. Although IIS sentinel site results 
are not intended to be representative of and generalizable to vaccination practices in the 
United States, rates have compared favorably to those from NIS (eg, influenza vaccination 
in children).11 For the 2008 to 2012 IIS sentinel site project period, 4 sentinel site areas 
(Arizona, Colorado, Oregon, and Wisconsin) consisted of subsets of each state; the other 4 
sentinel sites consisted of all of Michigan, Minnesota, North Dakota and New York City 
(Table 1). All sites are composed of geographically contiguous counties or zip code areas in 
which ≥85% of area vaccine provider sites that serve children and adolescents aged <19 
years are registered (enrolled) with the IIS. Sites must also have a minimum of 20,000 
children and at least 85% of children aged <19 years in their respective geographic areas 
who have at least 2 immunizations recorded in the IIS.12
Data
Using IIS sentinel site data, vaccination records were assessed by quarter according to 
calendar year (quarter 1, January–March; quarter 2, April–June; quarter 3, July–September; 
quarter 4, October–December) for all adolescents aged 11 to 12 years, 13 to 15 years, and 16 
to 18 years during quarter 4, 2009, through quarter 4, 2012. Birth cohorts were defined for 
each quarter to include all adolescents in the age groups. Age and vaccination status were 
determined as of the last day of the quarter; vaccinations given at any point until the end of 
the quarter were included in the analysis. Valid vaccinations were identified by CDC 
vaccine codes (CVX codes)13 and included bivalent HPV vaccine for girls and quadrivalent 
HPV vaccine for boys and girls. Each site processed individual vaccination data in 
accordance with business rules established by the American Immunization Registry 
Association Modeling of Immunization Registry Operations Workgroup.14 Within each age 
group, sites reported counts of the number of vaccine recipients by quarter, sex, and the 
number of HPV vaccine doses received to the CDC. Doses administered to 11 to 18-year-
olds were reported for October 17, 2009, through December 31, 2012, in monthly and 
weekly intervals. For male and female adolescents aged 13 to 15 years old at the end of the 
specified quarters (quarter 3, 2007, and quarter 4, 2011, for girls; quarter 4, 2011, for boys), 
sites reported the number of adolescents by year of age at which they received their first 
HPV vaccination, regardless of whether it was in that quarter or at an earlier time. This 
study was exempt from institutional review board review because it involved examination of 
secondary, deidentified data.
Analysis
Analyses were conducted using Microsoft Excel (2010) and SAS (SAS, Cary, NC) software. 
Vaccination coverage was calculated using denominators from the US Census intercensal 
population estimates.15 Use of census-based denominators to calculate adolescent 
participation in IIS and vaccination coverage levels has been described elsewhere.8,16 The 
unweighted average for the 8 sites (ie, average site-specific coverage) was calculated by 
summing the percentage of adolescents vaccinated at each site and dividing by 8, the total 
number of sites. Unweighted averages were used to allow for each site to be represented 
equally when calculating combined vaccination coverage. HPV series completion was 
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calculated as the number of adolescents who received 3 doses of HPV vaccine out of the 
total number who received at least 1 dose. Unlike in the NIS-Teen,4 series completion 
calculations included all adolescents who received ≥1 HPV doses in the denominator, 
regardless of the amount of time that had elapsed since the first HPV vaccination. Trend 
analyses were conducted for coverage in boys and girls using linear regression analyses 
(SAS, version 9.3 for Windows). Vaccination coverage estimates are expected to be lower 
among 11- to 12-year-olds because they are not older than the recommended vaccination age 
range and still have time to be vaccinated before their 13th birthday; however, the data 
provide useful information on patterns of uptake.
Weekly doses administered were calculated on the basis of the doses administered for the 
varying time periods. Intervals ranged from a single week up to month-long increments. In 
order to analyze the data in a consistent manner, a weekly average was calculated on the 
basis of the total number of doses administered for that month.
Results
Vaccine coverage data were available on an average of 2.9 million adolescents 11 to 18 
years of age per quarter. Overall among girls, 27.1% of 11- to 12-year-olds, 47.9% of 13- to 
15-year-olds, and 57.1% of 16- to 18-year-olds received ≥1 dose of HPV vaccine by 
December 31, 2012 (Table 2). Only 6.5% of 11- to 12-year-olds, 25.2% of 13- to 15-year-
olds, and 37.4% of 16- to 18-year-olds received all 3 doses of HPV vaccine. Of girls who 
initiated the series, 22.9% of 11- to 12-year-olds, 52.2% of 13- to 15-year-olds, and 65.5% 
of 16- to 18-year-olds received all 3 doses of HPV vaccine. Approximately 18% of male 
participants in all age groups received ≥1 dose of HPV vaccine by December 31, 2012. Of 
boys who initiated the series, 13.5% of 11- to 12-year-olds, 23.2% of 13- to 15-year-olds, 
and 24.7% of 16- to 18-year-olds received all 3 doses of HPV vaccine.
Figure 1 illustrates the trends in vaccination coverage from October 2009 to December 2012 
for female and male adolescents. Using linear regression techniques, the percentage of girls 
who received ≥1 HPV vaccine dose increased 4.8 percentage points for 11- to 12-year-olds, 
6.1 percentage points for 13- to 15-year-olds, and 14.1 percentage points for 16- to 18-year-
olds from quarter 4, 2009, to quarter 4, 2012. There was no significant change in the rate of 
increase in coverage among girls (P = .74) after the ACIP recommendation for routine 
vaccination of boys was released. Receipt of ≥1 dose of HPV vaccine in boys started to 
increase after licensure of quadrivalent vaccine for boys and ACIP guidance that vaccine 
could be used in boys in late 2009; ≥1 dose coverage increased to approximately 18% in 
male participants (16.4% for 11- to 12-year-olds, 20.7% for 13- to 15-year-olds, and 18.0% 
of 16- to 18-year-olds) a year after the ACIP recommendation for routine vaccination was 
released. For boys, there was no significant difference in coverage by age group (P = .43), 
but there was a significant increase in the rate of increase in coverage immediately after the 
ACIP recommendation for routine use in male adolescents (P = .003).
Among vaccinated 13- to 15-year-old girls, the percentage vaccinated at the recommended 
age of 11 to 12 years increased over time (Table 3). By the end of quarter 3, 2007, only 
9.9% of vaccinated 13- to 15-year-old girls received the first HPV vaccine dose before their 
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13th birthday, whereas 74.2% of vaccinated girls received the first HPV vaccine dose by 
their 13th birthday by the end of quarter 4, 2011. By the end of quarter 4, 2011, 27.3% of 
vaccinated 13- to 15-year-old boys received the first HPV vaccine dose before their 13th 
birthday. Quarter 3, 2007, and quarter 4, 2011, reflect time periods shortly after 
recommendations were made for routine use for girls and boys, respectively. Compared to 
the percentage of girls vaccinated at the recommended age by the end of October 2007, a 
larger percentage of boys were vaccinated at the recommended age by the end of December 
2011.
Figure 2 illustrates the doses administered to adolescents of both sexes from October 18, 
2009, to December 31, 2012, by week. For girls, vaccination peaked during July and August 
each year, coinciding with back-to-school time periods. Additionally, doses administered 
appear to have decreased at the end of November and did not increase until around March. 
The number of total doses administered increased approximately 3.5% each year from 2010 
to 2012. For boys, there was a clear increase in the number of doses administered, starting 
after the ACIP permissive recommendation and publication of guidance published in 
Morbidity and Mortality Weekly Report2 and smaller increases around the back-to-school 
period until summer 2012, when the doses administered to boys was similar to that for girls. 
The weekly number of doses administered to boys for all 8 sites combined surpassed the 
number of doses administered to girls by mid-September 2012 and remained higher through 
the end of 2012. Examination of individual sites revealed that the number of doses 
administered to boys only surpassed the number administered to girls in 6 of the 8 sites 
(January 2012 in New York City, May 2012 in Oregon, June 2012 in Arizona, North 
Dakota, and Wisconsin, and October 2012 in Michigan) (data not shown).
Discussion
This study used provider-verified vaccination data from IIS to examine HPV vaccine uptake 
in adolescents of both sexes from 2009 to 2012. These data provide information for girls 
from 3 to 5 years after ACIP recommended routine vaccination, and for boys from the time a 
permissive recommendation was made through 14 months after the ACIP recommended 
routine vaccination. Although some data have been published that examine vaccination of 
adolescent boys since the ACIP recommendation was made,4,17 this is to our knowledge the 
first study to present doses administered to adolescent boys compared to adolescent girls 
during the time period surrounding the ACIP recommendation for routine vaccination of 
boys. We found that doses administered to boys increased soon after the ACIP 
recommendation for routine use, whereas doses administered to girls showed seasonal 
variation and only small increases across the years studied. By the end of December 2012, 
the weekly number of doses administered to boys for all 8 sites combined surpassed the 
number of doses administered to girls.
Coverage in female adolescents increased during this time period, but the increases were 
small. The highest coverage was observed in 16- to 18-year-olds, and the percentage who 
received at least 1 dose in this age group increased from 42.9% to 57.1%. Our data on 
coverage among female adolescents are consistent with other studies.18–21 Also similar to 
other studies was the finding that older female adolescents were more likely to have initiated 
Cullen et al. Page 5













and completed vaccination.18–21 Provider recommendation is a major factor associated with 
HPV vaccine initiation.22–25 However, providers have a preference to vaccinate older 
female adolescents.26,27 Although overall coverage in girls remains below target levels and 
older adolescents have higher coverage than those aged 11 or 12 years, our data demonstrate 
that among those vaccinated, a larger percentage are getting vaccinated at the recommended 
age than were immediately after ACIP’s recommendation was released. In the fourth quarter 
of 2011, of 13- to 15-year-old girls who had received at least 1 dose of the vaccine, 74.2% 
had received their first dose before age 13. This represents a 7-fold increase over the third 
quarter of 2007. A larger percentage of vaccinated 13- to 15-year-old boys were vaccinated 
at the recommended age (27.3%) compared to 13- to 15-year-old girls (9.9%) at a similar 
time period after the recommendation for routine vaccination.
Soon after the vaccine was licensed for boys and a permissive recommendation was made 
by ACIP in 2009, the number of doses administered to boys started to increase. After ACIP 
made a routine recommendation, there were further increases. Nevertheless, 1-dose vaccine 
coverage in boys reached only 16% by the end of December 2012. Prelicensure studies 
indicated that acceptability would be high for vaccination of boys, but that parents and 
providers were more likely to vaccinate girls than boys.28 Similar to what was reported for 
girls, one survey found that providers would be less likely to strongly recommend 
vaccination to younger compared to older adolescent boys.28 However, we found that in 
contrast to girls, vaccination initiation and series completion was similar in all 3 age groups 
of boys. The lack of coverage difference by age among boys could be due to more provider 
familiarity with HPV vaccine when it was licensed for use in boys, or less discomfort 
discussing sexuality with male adolescents or their parents. However, boys vaccinated in 
this time period and their families are early adopters who may have different attitudes and 
behaviors than those who have not yet been vaccinated; they may be more likely to request 
vaccination, and the strength of the provider recommendation may have been less important. 
Further data will be needed to see if this trend in vaccine uptake among boys continues.
Examination of the number of doses administered to girls by week showed variations in 
vaccine administration during each year. The trends we found suggest the importance of 
back-to-school health care visits for administration of immunizations, even for those not 
required for school entry. None of the IIS sentinel sites had middle school entry 
requirements for HPV vaccination; nevertheless, the number of doses administered 
increased each summer before school started.29–31 All of the states in which the IIS sentinel 
sites are located had middle school entry requirements for a least 1 other vaccine 
recommended for adolescents.29,31 Of note, trends over each year were similar, and we did 
not observe any declines in uptake during specific years that would suggest an adverse 
impact of specific reports of safety concerns in the media or high visibility statements about 
the vaccine.32 Nevertheless, such publicity could have prevented increases in vaccine 
uptake. Doses administered to boys by week increased continuously during this time period 
and equaled or surpassed doses administered to girls in some areas.
A variety of interventions have been previously identified that could increase HPV 
vaccination coverage in adolescents. These include improving parental education, increasing 
the strength and consistency of provider recommendations, and preventing missed 
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opportunities.33 Although the proportion of adolescents who make preventive health care 
visits is low,34 the overall number of provider visits made by adolescents has increased over 
the past 2 decades,35 likely supported by the recommendation that adolescents get screened 
annually for a variety of behaviors and risk factors.36 However, the number of visits made 
by adolescents decreases with age. Most visits are to pediatricians and family practice 
physicians, with an increasing percentage of visits to gynecologists for girls and to 
subspecialists for boys in older adolescence.35 A recent analysis demonstrated that 84% of 
unvaccinated adolescent girls had at least 1 missed opportunity for the HPV vaccine.33 As 
adolescents age, the opportunities for vaccination decrease; thus, it is important for 
providers to minimize the number of missed opportunities for vaccination by providing 
vaccinations during both preventive- and acute-care visits.37
Results from this study were similar to results from NIS-Teen despite differences in the age 
groups examined and the geographic areas covered.6,18 However, there are some disparities 
in HPV coverage estimates (CDC, unpublished data) that might reflect differences in 
geographic assessment areas because not all sentinel site areas are comparable with the NIS-
Teen geographic areas, underreporting in the IIS, bias in NIS-Teen estimates, or a 
combination of these and other unidentified factors. Even if data on 13- to 17-year-olds were 
collected in this study, IIS and NIS-Teen data may not be directly comparable. Bias may 
remain in NIS-Teen estimates after weighting adjustments, nonresponse bias, and possible 
incomplete vaccination histories reported by providers.38–40
This study’s findings are subject to several important limitations. First, although provider 
enrollment in the IIS sentinel sites is high, the reporting completeness is unknown, and some 
provider sites do not contribute any immunization data to the IIS. This lack of reporting 
could have resulted in lower or higher HPV vaccination coverage in the IIS sentinel sites. 
Second, because study results are from 8 project areas, results are not generalizable to the 
overall US population (eg, the southeastern United States is not represented). However, the 
IIS sentinel sites are population based and include 2.9 million adolescents aged 11 to 18 
years residing across the United States, and the vaccination histories are provider verified. 
The data presented here are not weighted; however, the Sentinel Site Project’s goal is not to 
produce national estimates of HPV vaccination in adolescents. Results using weighted data 
would be skewed toward sites with larger populations. IIS may underestimate adolescent 
vaccination coverage because of information lacking from unenrolled providers, incomplete 
reporting by enrolled IIS providers, failure to include vaccinations administered at 
nontraditional locations, and disproportionate outmigration. However, IIS sentinel sites have 
>85% provider enrollment and strive to enroll all providers licensed to vaccinate in their 
jurisdiction, including traditional and complementary vaccinators. Although the 
denominators used in this analysis used consistent methodology from the US Census, use of 
those denominators may have led to artificially lower HPV vaccination coverage for sites 
with lower adolescent participation rates. Conversely, the use of US Census–determined 
denominators could result in overestimates of vaccination coverage if adolescents moved out 
of the state/city after vaccination and the IIS was unaware of the migration.
Despite these limitations, this is to our knowledge the first study to report on HPV 
vaccination using IIS and to examine trends in doses administered to boys and girls by week 
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since 2009. Although HPV vaccination coverage is increasing in both boys and girls, it is 
still below Healthy People 2020 target levels. It is important to continue to monitor uptake 
of HPV vaccine in both boys and girls, at both the national and local levels. The IIS can be 
useful for identifying trends in administration and coverage, especially when 
recommendations have changed recently, and can be used to target activities at the local 
level to improve vaccination.
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We report on human papillomavirus vaccination in adolescent boys using the 
Immunization Information System since the October 2011 Advisory Committee on 
Immunization Practices recommendation for routine use and to uniquely examine trends 
in doses administered to adolescent boys and girls by week since 2009.
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(A) Trends in HPV vaccination coverage for girls by age group, IIS sentinel sites, United 
States, quarter 4, 2009, to quarter 4, 2012. (B) Trends in HPV vaccination coverage for boys 
by age group, IIS sentinel sites, United States, quarter 4, 2009, to quarter 4, 2012.
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HPV vaccine doses administered to 11- to 18-year-olds by week and sex, IIS sentinel sites, 
United States, October 18, 2009, to December 31, 2012.
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Table 2
Average Percentage of Adolescents With Documented Receipt of HPV Vaccine as of Quarter 4, 2012, 







11–12 y ≥1 16.4 27.1
≥2 7.2 14.9
3 2.4 6.5
13–15 y ≥1 20.7 47.9
≥2 11.3 36.5
3 5.2 25.2
16–18 y ≥1 18.0 57.1
≥2 9.8 47.6
3 4.6 37.4
11–12 y 3-dose series completion* 13.5 22.9
13–15 y 3-dose series completion* 23.2 52.2
16–18 y 3-dose series completion* 24.7 65.5
HPV = human papillomavirus.
*
Percentage of male and female adolescents who received 3 doses among those who had at least 1 HPV dose as of quarter 4, 2012, regardless of 
time elapsed between first HPV vaccination and end of quarter.
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Table 3
Average Percentage of Vaccinated 13- to 15-Year-Old Adolescents at First HPV Vaccination, Quarter 3, 
2007, and Quarter 4, 2011, Immunization Information System Sentinel Sites, United States
Female Male
Age at First HPV Vaccination Quarter 3, 2007 Quarter 4, 2011 Quarter 3, 2007 Quarter 4, 2011
<11 y 0.1 8.7 NA 0.4
11 y 0.1 36.5 NA 5.4
12 y 9.7 29.0 NA 21.5
13 y 31.0 14.7 NA 30.8
14 y 35.6 8.7 NA 29.6
15 y 23.5 2.4 NA 12.3
NA = not applicable.
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